TareBio
YC S26San Francisco, US · Founded 2026 · 1 employees · 1 known investors
TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.
Founders & leadership· Y Combinator alumni (S26)
TareBio was founded in 2026 by Eta Atolia.
EA
Eta Atoliain𝕏FounderEta Atolia is Founder and CEO of TareBio, a biotechnology company developing personalized and population-level vaccines for cancer and infectious diseases. She holds an MD-PhD from UCLA-Caltech, where she developed a vaccine-development platform with Gates Foundation funding, and a BS in Biology from MIT, and has conducted research at the Koch Institute, Harvard Medical School, and the Weizmann Institute.
Investors · 1
Images
In the news
Frequently asked questions
- What does TareBio do?
- TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.
- Who founded TareBio?
- TareBio was founded by Eta Atolia in 2026.
- Who are TareBio's investors?
- TareBio's investors include Y Combinator.
- Where is TareBio headquartered?
- TareBio is headquartered in San Francisco, US.